The main targets were GABRA1, PTGS2, SLC6A2, CHRM1, ADRA1B, CHRM2, CHRM3, ADRA1A, ADRB1, ADRB2, PTGS1, and SLC6A3 that conducted with neuroactive ligand-receptor interaction pathways, signaling pathways, and metabolism pathways related to analgesic, anticonvulsant, and repair reduction of cholinergic neurons and eliminate the inflammatory response to reduce the secretion of neurotoxic inflammatory cytokine to cure diseases related to AD and insomnia. The gene discussed is SLC6A3; the disease is insomnia measurement.